Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Agios PharmaceuticalsAGIO -3.98%47 Debt-to-Equity is 0.03 as of Jun. 2026, which is 63% below its 10-year median of 0.08. GuruFocus rates AGIO with a GF Score™ of 47/100 and a GF Value™ of $87.73 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 967 Biotechnology companies, Agios Pharmaceuticals ranks better than 88% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Agios Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
AGIO'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.08 Max: 0.26
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of Agios Pharmaceuticals was 0.26. The lowest was 0.02. And the median was 0.08.
AGIO's Debt-to-Equity is ranked better than 88% of 967
companies
in the Biotechnology industry
Industry Median: 0.16
vs AGIO: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Agios Pharmaceuticals Debt-to-Equity Related Terms
Agios Pharmaceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Agios Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AGIO vs BHVN, VRDN, ZLAB: Debt-to-Equity Comparison
For the Biotechnology subindustry, Agios Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agios Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Agios Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals (AGIO) has a Debt-to-Equity of 0.03 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Agios Pharmaceuticals and its competitors. This is 63% below median its historical median of 0.08. Over the past decade, Agios Pharmaceuticals' Debt-to-Equity has ranged from 0.02 to 0.26. According to the industry distribution chart, Agios Pharmaceuticals ranks #116 out of 967 companies in the Biotechnology industry, placing it in the top 12%.
Is Agios Pharmaceuticals' Debt-to-Equity too high?
Agios Pharmaceuticals' current Debt-to-Equity of 0.03 is 63% below median its 10-year median of 0.08. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.26. The Biotechnology industry median Debt-to-Equity is 0.16. Agios Pharmaceuticals' value of 0.03 is 81.3% below this industry median. Based on the distribution chart, Agios Pharmaceuticals ranks #116 out of 967 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Agios Pharmaceuticals has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Debt-to-Equity compare to BHVN and VRDN?
According to the Biotechnology industry distribution chart, Agios Pharmaceuticals ranks #116 out of 967 companies for Debt-to-Equity. This places Agios Pharmaceuticals in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Agios Pharmaceuticals' value of 0.03 is 81.3% below this benchmark. Historically, Agios Pharmaceuticals' own Debt-to-Equity has ranged from 0.02 to 0.26 over the past decade. While the company's 10-year median is 0.08 vs. the industry median of 0.16, Agios Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agios Pharmaceuticals's current Debt-to-Equity of 0.03 is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Agios Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agios Pharmaceuticals's current Debt-to-Equity is 0.03, which is 63% below median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Agios Pharmaceuticals (AGIO) is currently considered Possible Value Trap. The stock's GF Value™ is $87.73, compared to a current price of $31.45 — trading 64.2% below its estimated fair value. The current Debt-to-Equity is 0.03, which is 63% below median its 10-year median of 0.08 and 81.3% below the Biotechnology industry median of 0.16. Agios Pharmaceuticals' overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Agios Pharmaceuticals (AGIO), the current Debt-to-Equity is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (AGIO) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of $31.45 is trading 64.2% below its estimated GF Value™ of $87.73.
GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.
Key valuation signals for AGIO:
Debt-to-Equity: 0.03 (63% below median its 10-year median of 0.08)
GF Value™: $87.73 vs. price of $31.45 (64.2% below fair value)
Industry Position: 81.3% below the Biotechnology median (#116 of 967)
No single metric tells the full story. See the AGIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
47GF Score
Get the complete analysis for AGIO
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGIO has been successfully added to your 
